Home / Oligonucleotides and Peptides / Discovery / Oligonucleotide
Oligonucleotide CRDMO Services
Designed to handle the challenging parts of oligonucleotide development: modifications, conjugation, and scale-up.
Integrated Execution for Complex Oligonucleotides
WuXi TIDES provides integrated CRDMO services for oligonucleotide therapeutics, supporting programs from discovery through clinical development and commercial supply. The platform brings chemistry, CMC, analytical, drug product, and manufacturing teams together to align early technical decisions with downstream requirements and documentation.
Experience spans a broad range of oligonucleotide modalities and chemistries, including highly modified backbones and conjugated oligonucleotides. In-house supply of critical building blocks (amidites and ligands) and established process and analytical approaches help reduce external dependency and support consistent progression from candidate selection through long-term supply.
Oligonucleotide Drug Development & Manufacturing Services
Discovery Synthesis
CMC Development
Oligonucleotide-Based Conjugates
Clinical Supply
Related content
Quantum Mechanics for Organic Chemists
Quantum Mechanics, Molecular Orbital Theory in particular, enables us to understand organic reactions at deeper levels.
Frequently Asked Questions
QM Magic Class | Chapter 38 Over the years, we received a lot of questions from our readers, below are...
WuXi STA Forms Strategic Partnership with Beta Pharma
STA will Accelerate Process R&D and Manufacturing of Late Phase and Commercial Targets STA Pharmaceutical Co., Ltd., (WuXi STA) –...